1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Alkem Laboratories Limited

Alkem Laboratories Limited

ALKEM.BO
Alkem Laboratories LimitedIN flagBombay Stock Exchange
5,592.40
INR
+20.90
- -
667.67BMarket Cap

Total Valuation

Alkem Laboratories Limited carries a market capitalization of 667.67B, placing it among publicly traded companies globally. Its enterprise value stands at 609.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap667.67B
Enterprise Value609.97B

Share Statistics

Alkem Laboratories Limited currently has 119.57M shares outstanding.

Shares Outstanding119.57M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Alkem Laboratories Limited trades at a trailing price-to-earnings ratio of 27.55. The price-to-sales ratio is 4.31, and the price-to-book ratio stands at 2,652.19.

PE Ratio27.55
PS Ratio4.31
PB Ratio2,652.19
P/TBV Ratio4.72
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Alkem Laboratories Limited trades at an EV/EBITDA multiple of 23.25 and an EV/FCF ratio of 462.86. The EV/Sales ratio of 4.15 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 23.25 provides insight into valuation relative to core operating earnings.

EV / Sales4.15
EV / EBITDA23.25
EV / EBIT23.25
EV / FCF462.86

Financial Position

Alkem Laboratories Limited maintains a current ratio of 2.55, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.27, indicating elevated leverage, while an interest coverage ratio of 16.32 demonstrates strong ability to service its debt obligations.

Current Ratio2.55
Quick Ratio1.04
Debt / Equity14.27
Debt / EBITDA0.78
Interest Coverage16.32

Financial Efficiency

Alkem Laboratories Limited posts a return on equity of 45.94 and a return on invested capital of 14.21.

Return on Equity (ROE)45.94
Return on Assets (ROA)11.94
Return on Invested Capital (ROIC)14.21
Return on Capital Employed (ROCE)33.05
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.63

Taxes

Over the trailing twelve months, Alkem Laboratories Limited has paid 5.18B in income taxes, reflecting an effective tax rate of 18.03.

Income Tax5.18B
Effective Tax Rate18.03

Stock Price Statistics

Alkem Laboratories Limited's stock has gained approximately 14.7724% over the past 52 weeks. The 50-day moving average sits at 5,414.52, while the 200-day moving average is 5,527.20.

Beta (5Y)N/A
52-Week Price Change14.7724%
50-Day Moving Average5,414.52
200-Day Moving Average5,527.20
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Alkem Laboratories Limited generated 147.12B in revenue and converted that into 23.02B in net income, yielding earnings per share of 196.63. EBITDA reached 26.23B, while operating income came in at 26.23B.

Revenue147.12B
Gross Profit96.20B
Operating Income26.23B
Pretax Income28.71B
Net Income23.02B
EBITDA26.23B
EBIT26.23B
Earnings Per Share (EPS)196.63

Balance Sheet

Alkem Laboratories Limited holds 49.93B in cash and equivalents against 20.47B in total debt, resulting in a net debt position of 13.76B. Total book value stands at 239.10M, with working capital of 74.28B providing operational flexibility.

Cash & Cash Equivalents49.93B
Total Debt20.47B
Net Debt13.76B
Equity (Book Value)239.10M
Book Value Per Share2.00
Working Capital74.28B

Margins

Alkem Laboratories Limited operates with a gross margin of 65.38, reflecting its pricing power and cost economics. The operating margin of 17.83 and net profit margin of 15.65 provide insight into operational efficiency.

Gross Margin65.38
Operating Margin17.83
Pretax Margin19.51
Profit Margin15.65
EBITDA Margin17.83

Scores

Alkem Laboratories Limited posts an Altman Z-Score of 7.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score7.45